| Combined treatment (n = 15) | Aumolertinib (n = 50) | P-value |
---|---|---|---|
N (%) | N (%) | ||
Gender | p = 0.25 | ||
Male | 9 (60%) | 21 (42%) | Â |
Female | 6 (40%) | 29 (58%) | Â |
Age | p = 0.91 | ||
Median Age | 65 | 67 | Â |
 < 70 years | 9 (60%) | 29 (58%) |  |
 ≥ 70 years | 6 (40%) | 21 (42%) |  |
Stage prior therapy | p = 0.77 | ||
Stage II | 0 | 2 (4%) | Â |
Stage III | 3 (20%) | 10 (20%) | Â |
Stage IV | 12 (80%) | 38 (76%) | Â |
EGFR | p = 0.57 | ||
Mutant | 15 (100%) | 50 (100%) | Â |
Del19 | 9 (60%) | 25 (50%) | Â |
L858R | 6 (40%) | 25 (50%) | Â |
Tumor response | p = 0.04 | ||
Complete response (CR) | 0 (0%) | 0 (0%) | Â |
Partial response (PR) | 14 (93.3%) | 32 (64%) | Â |
Stable disease (SD) | 1 (6.7%) | 14 (28%) | Â |
Progressive disease (PD) | 0 (0%) | 4 (8%) | Â |